A new trial has compared the two most prominent tests, showing that both have clear predictive ability, but leaving several other questions unanswered so far.
The agreement grants MDxHealth the rights to manufacture and market the phosphodiesterase-4D7 biomarker as a prognostic test.
Exome sequencing on tumors from metastatic, castration-resistant prostate cancer cases responding to immunotherapy led to homologous recombination defects.
In a pan-cancer analysis, Lynch syndrome genes were mutated more often than anticipated in tumors with high or intermediate levels of microsatellite instability.
Informaticians at Spain's National Cancer Research Centre develop a methodology for evaluating likely drug efficacy based on specific patient genotypes.
A University of Michigan-led team found that the lncRNA ARLNC1 forms a feedback loop with the androgen receptor to promote progression in prostate cancer.
A small study finds differences between three genomic prostate cancer tests, Medscape reports.
The method uses hydrogel encapsulation, which mimics a tissue sample, in order to allow circulating tumor cell isolation and extraction through laser dissection.
At least half a dozen cancer phenotypes showed significant associations with GWAS variant-based polygenic risk scores in a new phenome-wide association study.
GenomeDx will test its Decipher GRID database of cancer genomic profiles with samples from Janssen-run prostate cancer clinical trials.
The US National Institutes of Health's All of Us project awarded $4.6 million to the company Color to develop a genetic counseling resource for the program.
The Times of India reports on a pilot study that used genomic testing to determine whether patients had drug-resistant tuberculosis.
New guidelines say that more women may benefit from genetic testing for hereditary breast or ovarian cancer, according to the Los Angeles Times.
In Cell this week: small proteins identified among human microbiome, role for tumor microbes in pancreatic cancer survival, and more.